Welcome to our dedicated page for Rezolute news (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.
Rezolute, Inc. (Nasdaq: RZLT) is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), including congenital and tumor forms of the condition. The RZLT news feed highlights company announcements, clinical trial updates, regulatory interactions and corporate developments related to its lead antibody therapy, ersodetug.
Investors and followers of Rezolute can use this page to review detailed updates on key Phase 3 programs such as the sunRIZE study in congenital hyperinsulinism and the upLIFT study in tumor hyperinsulinism. Company news has included topline results from sunRIZE, insights into pharmacologic activity and placebo effects in glucose endpoints, and plans to discuss the full dataset with the U.S. Food and Drug Administration under Breakthrough Therapy Designation.
News items also cover the evolution of the upLIFT trial design after alignment with the FDA on a streamlined, single-arm, open-label approach, as well as data from an Expanded Access Program in tumor HI that informed this strategy. In addition, Rezolute regularly reports on financial results, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), participation in healthcare and investor conferences, and leadership appointments that support its development and potential commercialization plans for ersodetug.
By following RZLT news, readers can track how Rezolute communicates progress in its clinical programs, interprets study findings, and engages with regulators and the investment community. This page provides a centralized view of the company’s press releases and related disclosures, offering context for the ongoing development of ersodetug in rare hyperinsulinism indications.
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company, announced that CEO Nevan Charles Elam will present at two virtual investment conferences. The BTIG Virtual Biotechnology Conference is scheduled for August 10, 2021, at 12:00 p.m. ET, while the Canaccord Genuity 41st Annual Growth Conference will take place on August 12, 2021, at 3:30 p.m. ET. A live webcast for the latter will be available on the company’s Investors page, with a replay accessible for 90 days after the event.
Rezolute is focused on developing therapies for metabolic diseases, including its lead asset, RZ358, for congenital hyperinsulinism.
Rezolute, Inc. (Nasdaq: RZLT) has been added to the Russell Microcap® Index, effective June 28, 2021. This inclusion allows Rezolute to reach a broader investor base, as the Russell indexes are widely used for benchmarking in investment management. The Russell Microcap® Index listing lasts one year and enhances visibility for Rezolute’s therapeutic developments, particularly RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. With $10.6 trillion in assets benchmarked against Russell indexes, this move is expected to positively affect the company's market presence.
Rezolute, Inc. (Nasdaq: RZLT) has announced that CEO Nevan Charles Elam will present at two virtual investor conferences. The first event is the Jefferies Virtual Healthcare Conference on June 4, 2021, at 12:30 p.m. ET, followed by the JMP Securities Life Sciences Conference on June 17, 2021, at 1:30 p.m. ET. Interested parties can access live webcasts on the company's IR Calendar page, with replays available for 30 days afterward.
Rezolute is focused on developing treatments for metabolic diseases, specifically its lead asset RZ358 aimed at congenital hyperinsulinism.
Rezolute, Inc. (Nasdaq: RZLT) has appointed Davelyn Hood, MD, as Director of Scientific and Patient Affairs, enhancing its leadership team for the RZ358 clinical program targeting congenital hyperinsulinism. Dr. Hood brings over a decade of experience in the field and a personal connection to the disease as a parent of a child affected by it. RZ358, currently in a Phase 2b trial, aims to regulate insulin levels in patients with this rare condition. The therapy has received Orphan Drug and Pediatric Rare Disease designations in both the US and EU.
Rezolute, Inc. (RZLT), a clinical-stage biopharmaceutical company, has appointed Dr. Quan Dong Nguyen to its Scientific Advisory Board. Dr. Nguyen, a prominent expert in retinal diseases, will provide strategic counsel for RZ402, an oral plasma kallikrein inhibitor aimed at treating diabetic macular edema (DME). His extensive background includes leading pivotal clinical trials and contributing to the approval of existing therapies such as EYLEA and Lucentis. This addition is expected to enhance Rezolute's clinical development strategy and address unmet needs in DME treatment.
Rezolute, Inc. (RZLT), a clinical-stage biopharmaceutical company, reported its financial results for Q3 FY2021, ending March 31, 2021. The company continues to progress its pipeline, including RZ358 and RZ402. Topline results from a Phase 1 study of RZ402 indicate potential for daily oral dosing in diabetic macular edema treatment. Cash reserves stand at $32 million. R&D expenses rose slightly to $3.8 million, while G&A expenses increased to $1.7 million. The net loss for the quarter was $3.7 million ($0.44 per share), an improvement from a $5 million loss ($0.86 per share) in Q3 2020.
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company, will present at the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021. The presentation will be accessible on-demand at 8:00 AM ET and available for 90 days on the company’s Investors section. Rezolute is focused on developing novel therapies for chronic glucose imbalance, with its lead product, RZ358, undergoing Phase 2b trials for congenital hyperinsulinism. Additionally, RZ402 is being developed for diabetic macular edema. For more details, visit their website.
Rezolute, Inc. (Nasdaq: RZLT) announced positive topline results from its Phase 1a clinical study of RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema (DME). The study showed that RZ402's single dose led to plasma concentrations significantly exceeding target levels, supporting the advancement to a Phase 1b study. The drug was generally safe and well-tolerated, with no serious adverse events reported. The results suggest RZ402 could provide an effective treatment option for DME patients, offering improved delivery and compliance.
Rezolute has secured a $30 million debt financing agreement with SLR Capital Partners to enhance its funding capabilities for advancing targeted therapies for rare and metabolic diseases. The initial $15 million was funded upon closing, with an interest-only period lasting 24 months. The remaining funds may be accessed upon meeting specific milestones. CEO Nevan Elam highlighted that this facility provides non-dilutive operational flexibility as they progress their pipeline, including lead candidate RZ358, currently in Phase 2b development.
Rezolute, Inc. (RZLT) announced positive results from its Phase 2a study of RZ358 for post-gastric bypass hypoglycemia at ENDO 2021. The study demonstrated a significant over 50% improvement in hypoglycemia, achieving near-normal glucose levels. RZ358 was safe, well-tolerated, and did not induce hyperglycemia. The pharmacokinetic model supports the potential effectiveness of RZ358 in future trials, including those for congenital hyperinsulinism. Rezolute is advancing RZ358, which has received Orphan Drug Designation in multiple regions.